M-A: Tocilizumabe na COVID-19 – “Há algumas evidências de que, em pacientes hospitalizados com COVID-19, o uso de tocilizumabe possa estar associado com o benefício de mortalidade de curto prazo, mas são necessários mais dados de alta qualidade.”

Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials – Intensive Care Medicine

Comentário no Twitter

Tocilizumab as IL-6 antagonist in hospitalized #COVID19 pts, SR/MA/TSA:
➡️10 RCTs/6493 pts (52.2% ➡️ tocilizumab)
➡️some evidence suggests tocilizumab may be associated with short-term mortality benefit
➡️tocilizumab may prevent disease progression to MVhttps://t.co/sWR4Y351sl pic.twitter.com/JPD31Nb5rn

— Intens Care Med (@yourICM) May 22, 2021